Forgot your password?

Forgot your username?

database > company
Kenta Biotech AG
Biotech Specialty Pharma
Rehhagstrasse 79
Bern, CH-3018 Switzerland
phone:+41 (0) 58 680 52 53
fax:+41 (0) 58 680 52 51
Symbol Private
Founded 2006
Employees 17
www.kentabiotech.com
Research Sector Biotech Specialty Pharma
Summary Description
Monoclonal antibody biotechnology treats infectious diseases.
Management
Violetta Georgescu-Kyburz, CEO Michael Rudolf, CSO Horst Blasey, Head Operations Laurence Blazianu, CBO
Keywords
Hospital infections, MRSA, Pseudomonas, infectious disease, fully human monoclonal antibodies

Comment | Printable Version | Modify profile |
Updated: Aug. 22, 2011

Description
Kenta Biotech focuses on the discovery and development of innovative, fully-human monoclonal antibodies targeting bacteria and viruses. Kenta's pipeline includes a series of antibodies that target the most difficult to treat pathogens causing life-threatening hospital-acquired infections such as P. aeruginosa, S. aureus and A. baumannii. Kenta's antibodies are intended as life-saving treatments for the most vulnerable patients in the ICU. These antibodies are designed to target bacteria independently of resistance to antimicrobial therapies and eliminate the infection. Kenta's first-in-class, targeted therapies have the potential to revolutionize the treatment of hospital-acquired infections, by reducing mortality and shortening ICU and hospital stays.
Products / Services
Broad pipeline of innovative fully-human monoclonal antibodies including KBPA101: a highly specific lgM monoclonal antibody against Pseudomonas aeruginosa (P. aeruginosa) serotype O11 which has successfully completed Phase IIa clinical trials KBPA102-104: three additional antibodies targeting P. aeruginosa of serotypes IATS-O1, -O6 and serogroup 2 (comprised of closely related serotypes -O2, -O5 and -O16) KBSA301: a highly specifc IgG monoclonal antibody targeting Staphylococcus aureus (S. aureus) infections entering clinical development in 2011 Innovative test assay technology: A proprietary, real-time PCR diagnostic kit for rapid identification of P. aeruginosa serotypes developed in collaboration with Roche Diagnostics A range of novel product candidates in pre-clinical development, targeting some of the most serious pathogens causing hospital-acquired infections (?HAIs?) such as S. aureus and Acinetobacter baumannii (A. baumannii) as well as an antibody targeting Respiratory Syncytial Virus (?RSV?)
Technology / Differentiation
Kenta's proprietary MAblgX® technology enables the generation and selection of fully-human monoclonal antibodies Due to the technology?s unique ability to capture and immortalize human B-cells from convalescent donors, Kenta's antibodies are immunologically highly relevant and are expected to have a superior efficacy and safety profile relative to other therapies treating hospital-acquired infections.
Market / Customers
Life-threatening Hospital-infections/Intensive Care/Orphan Drug
Competitors / Substitutes / Alternatives
Intercell MedImmune
Funding
Private Financing - rounds A&B